Home /
WU, Hong
E-mail: hongwu(AT)pku.edu.cn
Chair Professor
Lab Phone: +86-10-62765646
Lab Address: LUI CHE WOO BUILDING,Peking University, No.5 Yiheyuan Road, Haidian District,Beijing, P.R.China 100871
Lab Homepage:
Personal Homepage:
Dr. Wu is a chair professor and dean of the School of Life Sciences at Peking University, and a senior investigator of the Peking-Tsinghua Center for Life Sciences. Before returning to China, Dr. Hong Wu was David Geffen Professor of Molecular and Medical Pharmacology and director of the Institute for Molecular Medicine at the David Geffen School of Medicine at UCLA.
Dr. Wu received her medical training from Beijing Medical College, China, and her PhD in Biological Chemistry from Harvard Medical School. After postdoctoral training as a Damon Runyon-Walter Winchell postdoctoral fellow at the Whitehead Institute for Biomedical Research, MIT, she joined UCLA as a faculty member.
A major research focus of Dr. Wu’s laboratory is to study the molecular mechanism of PTEN tumor suppressor controlled tumorigenesis. By generating tissue-specific PTEN deficient animal models, Dr. Wu’s laboratory elucidated the important role of PTEN in regulating stem cell self-renewal, proliferation, and survival, as well as its roles in controlling the PI3K pathway. These models have been used for preclinical studies of new therapeutic agents and for identifying biomarkers for human prostate cancers.
Degree   Year       Major             Institution

Ph.D    1984-1991     Molecular Genetics      Harvard Medical School & Whitehead Institute for
                              Biomedical Research, MIT

Bachelor   1978-1983     Medicine           Beijing Medical College
Professional Experience
2013-present  Senior Investigator, Center for Life Science, Peking University
2013-2023   Chair Professor & Dean, School of Life Sciences, Peking University
2008-2013    Associate Director then Director, Institute for Molecular Medicine, David Geffen School of Medicine, UCLA
2009-2013    David Geffen Chair Professor, David Geffen School of Medicine, UCLA
2008-2011    Vice Chair, Department of Molecular and Medical Pharmacology, UCLA
2006-2013    Co-Director, Cancer Stem Cell Program, Eli and Edythe Broad Center of Regenerative Medicine and Stem
          Cell Research, UCLA
2004-2013    Associate Director, Genitourinary Oncology Program Area, Jonsson Comprehensive Cancer Center, UCLA
2003-2012    Director, Molecular and Genetic Technology Center, UCLA
1997-2004    Assistant Investigator, Howard Hughes Medical Institute
1996-2013    Assistant Professor to Tenured Full Professor, Department of Molecular and Medical Pharmacology, UCLA
1996-2003    Member, Jonsson Comprehensive Cancer Center and Molecular Biology Institute, UCLA
1991-1996    Postdoctoral Fellow, Whitehead Institute for Biomedical Research, MIT
Honors and Awards
1/2011      Fellow of American Association for the Advancement of Science
4/2009      David Geffen Endowed Chair for Medical Research
8/2008      Adelson Foundation Award
6/2008      Prostate Cancer Foundation Award
7/2006      Brain Tumor Society Program Award
7/2006      Waxman Foundation Program Award
1/2004      Prostate Cancer Foundation Award
6/2003      James S. McDonnell Foundation Award
6/2002      The Brain Tumor Society Award
1/2000      CaPCure Research Award
1/2000      1999 Cheryl Whitlock Memorial Prize, Palo Alto, CA
7/1997 - 8/2004  Howard Hughes Assistant Investigator Award, Chevy Chase, Maryland
6/1997 - 5/1999  The V Foundation Scholar Award, Cary, North Carolina
5/1997 - 4/2001  Pew Scholar Award (relinquished due to the duplication with the HHMI Award), San Francisco, California
7/1996      Stop Cancer-Next Generation Award, Los Angeles, California
11/1992-10/1995 Damon Runyon-Walter Winchell Postdoctoral Fellowship, New York, NY
5/1991      Radcliffe Grant for Graduate Women, Harvard, University, Cambridge, MA
6/1985 - 5/1990  Lucille P. Markey Fellowship, Harvard Medical School, Boston, MA
7/1984 - 6/1987  CUSBEA exchange studentship, Harvard Medical School and CUSBEA Program
9/1978 - 7/1983  Highest Honors, Beijing Medical College, Beijing, P.R.China
Professional Society Affiliations
1999 Steering committee member, Mouse Model of Human Cancer Consortium, NCI (1999-2004)
2004 Steering committee member and chair of the prostate cancer organ site committee, Mouse Model of
Human Cancer Consortium, NCI (2004-2009)
2006 Member of the board directors and Secretary General, The Chinese Biomedical Investigators Society
2007 Member of the external advisory board, Roswell Park Cancer Institute (2007- present)
2007 Member and co-Chair, Honors and Awards Committee, Chinese-American Engineers and Scientists
Association of Southern California
2008 Member of the board directors, Ray Wu Memorial Foundation (2008-2012)
2011 Member of steering committee, NCI Tumor Microenvironment Consortium (2011-2016)
2013 Member of Global Advisory Board, Movember (2013-2016)
2014 Member of International Affair Committee, AACR
Grant Review/Study Section Membership
2000 Ad hoc reviewer, Michigan Life Sciences Corridor Fund
2002 Ad hoc reviewer, National Cancer Institute
2003 Panelist, The Chinese National Science Foundation Review Committee (2003-2004)
2004 Panelist, The Chinese National Science Foundation Review Committee for Medicine (2004-2008)
2008 Member, Scientific Review Board, Chinese Academy of Sciences (2005-2012)
2012 Member of review committee, the Cancer Prevention and Research Institute of Texas (CRRIT)
Meeting Organizers and Session Chairs
1999 Organizer and section chair, the US National Academy of Sciences Committee
   for American-Chinese Frontier of Sciences, Beijing (1999) Irvine, CA (2000)
2001 Section Co-chair, Frontiers of Biological Sciences in the 21st Century, Beijing, P.R.China
2002 Section Co-chair, The Ray Wu Society meeting, San Diego, CA
2004 Co-organizer, NCI-MMHCC semi-annual meeting, Los Angeles, CA
2004 Co-organizer, The 1st International Meeting on PTEN Tumor Suppressor Gene, Arizona
2007 Co-Chair, subcommittee of the 2007 American Association for Cancer Research (AACR) Program
2007 Organizer, Frontiers of Biomedical Sciences Symposium, Beijing, China
2008 Section chair, mTOR Signaling: From Cancer to CNS Function, Bethesda, MD
2008 Organizer and section chair: An AACR-ASH joint workshop on PI3-Kinase: A Common Pathway for
   Hematologic Malignancies and Solid Tumors. Lansdowne, VA
2009 Organizer and section co-chair, 2009 NCI Translational Medicine Meeting, VA
2010 Section chair, Cold Spring Harbor meeting on “PTEN Tumor Suppressor”, NY
2014 Program committee member and section chair, AACR symposium on “New Horizons in Cancer Research”,
   Shanghai, China
2015 Program committee member and section chair, AACR symposium on “New Horizons in Cancer Research”,
   Shanghai, China
Research Interests
PTEN is the second most frequently deleted tumor suppressor gene in human cancers. PTEN mutation also was found to be the cause of three autosomal dominant tumor predisposition syndromes. A major focus of Dr. Hong Wu's research is to study the molecular mechanism of PTEN controlled tumorigenesis. For this, she has undertaken a combination of molecular genetics, cell biology and biochemical approaches. By analyzing cells and animals lacking the PTEN tumor suppressor, Wu and her colleagues have demonstrated that PTEN negatively regulates stem cell self-renewal, proliferation and survival. Thus, their study provides a strong link between stem cell biology and cancer biology and suggests that tumors may originate through the transformation of stem cells. They also established various animal models for human cancers, including T-ALL and prostate cancer models. These murine cancer models offer unique tools for both exploring the molecular mechanism underlying human cancers and for the development of new therapies.
Representative Peer-Reviewed Publications
1. Zhu, Haichuan; Dong, Bingjie; Zhang, Yingchi; Wang, Mei; Rao, Jianan; Cui, Bowen; Liu, Yu; Jiang, Qian; Wang, Weitao; Yang, Lu; Yu, Anqi; Li, Zongru; Liu, Chao; Zhang, Leping; Huang, Xiaojun; Zhu, Xiaofan; Wu, Hong. Integrated genomic analyses identify high-risk factors and actionable targets in T-cell acute lymphoblastic leukemia. Blood Science 4, 16-28, doi:10.1097/bs9.0000000000000102 (2022).
2. Xue, Yue; Yang, Ying; Tian, Tao, Quan, Hui; Liu, Sirui; Zhang, Ling; Yang, Lu; Zhu, Haichuan; Wu, Hong; Gao, Yiqin. Computational characterization of domain-segregated 3D chromatin structure and segmented DNA methylation status in carcinogenesis. Mol Oncol 16, 699-716, doi:10.1002/1878-0261.13127 (2022).
3. Zhi, Q., Xu, Z., Zhang, L., Zou, Y., Li, J., Yan, W., Li, C., Liu, N. and Wu, H. Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment. Nat Commun. 2022 Jan 10;13(1):182. PMID: 35013322
4. Yang, L., Chen, F., Zhu, H., Chen, Y., Dong, B., Shi, M., Wang, W., Jiang, Q., Zhang, L., Huang, X., Zhang, M., Wu, H. (2021) 3D Genome Alterations Associated with Dysregulated HOXA13 Expression in High-Risk T-Lineage Acute Lymphoblastic Leukemia. Nat Commun. 2021 Jun 17;12(1):3708. PMID: 34140506
5. Cheng. J., Huang. Y., Zhang. X, Yu. Y., Wu. S., Jiao J., Tran. L., Zhang, W., Liu. R., Zhang, L., Wang. M., Wang, M., Yan, W., Wu, Y., Chi, F., Jiang. P., Zhang. X., and Wu, H.(2020) TRIM21 and PHLDA3 Negatively Regulate the Crosstalk between the PI3K/AKT Pathway and PPP Metabolism. Nat Commun. 20;11(1):1880. PMID: 32312982
6. Wu, Y., Zhu, H., and Wu, H. (2019). PTEN in Regulating Hematopoiesis and Leukemogenesis. Cold Spring Harb Perspect Med. PMID:31712222.
7. Zhu, H., Zhang, L., Wu, Y., Dong, B., Guo, W., Wang, M., Yang, L., Fan, X., Tang, Y., Liu, N., Lei X., and Wu H. (2018). T-ALL leukemia stem cell 'stemness' is epigenetically controlled by the master regulator SPI1. Elife 7. PMID: 30412053
8. Zou, Y., Qi, Z., Guo, W., Zhang, L., Ruscetti, M., Shenoy, T., Liu, N., and Wu, H. (2018). Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3Kalpha/beta/delta Inhibitor BAY1082439. Mol Cancer Ther 17, 2091-2099. PMID: 30045927
9. Shenoy, T.R., Boysen, G., Wang, M.Y., Xu, Q.Z., Guo, W.L., Koh, F.M., Wang, C., Zhang, L.Z., Wang, Y., Gil, V., Aziz, S., Christova, R., Rodrigues, D.N., Crespo, M., Rescigno, P., Tunariu, N., Riisnaes, R., Zafeiriou, Z., Flohr, P., Yuan, W., Knight, E., Swain, A., Ramalho-Santos, M., Xu, D.Y., de Bono, J. and Wu, H. (2017) CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair. Ann Oncol. Jul 1;28(7):1495-1507.PMID: 28383660
10. Schubbert S., Jiao, J., Ruscetti, M., Nakashima, J., Wu, S., Lei, H., Xu, Q., Yi, W., Zhu, H., Wu, H. (2016) Methods for PTEN in Stem Cells and Cancer Stem Cells Methods Mol. Biol. 1288:233-85. PMID:27033080
11. Ruscetti, M., Dadashian, E.L., Guo, W., Quach, B., Mulholland D.J., Park J.W., Tran, L.M., Kobayashi, N., Bianchi-Frias, D., Nelson, P.S., Xing, Y. and Wu, H. (2016) HDAC Inhibition Impedes Epithelial-Mesenchymal Plasticity and Suppresses Metastatic, Castration-Resistant Prostate Cancer. Oncogene. 2016.7.21, 35(29): 3781~3795 PMID:26640144
12. Ruscetti, M., Quach, B., Dadashian, E.L., Mulholland, D.J. and Wu, H. (2015) Tracking and functional characterization of EMT and mesenchymal-like tumor cells in prostate cancer metastasis. Cancer Res. 75:2749-59. PMCID:PMC4490048.
1. 11. Schubbert S, Cardenas A, Chen H, Garcia C, Guo W, Bradner JE, Wu H.  Targeting the MYC and PI3K pathways eliminates leukemia-initiating cells in T cell acute lymphoblastic leukemia. (2014) Cancer Res74:7048-59.PMCID:PMC4258248
13. Pulido R, Baker SJ, Barata JT, Carracedo A, Cid VJ, Chin-Sang ID, Davé V, den Hertog J, Devreotes P, Eickholt BJ, Eng C, Furnari FB, Georgescu MM, Gericke A, Hopkins B, Jiang X, Lee SR, Lösche M, Malaney P, Matias-Guiu X, Molina M, Pandolfi PP, Parsons R, Pinton P, Rivas C, Rocha RM, Rodríguez MS, Ross AH, Serrano M, Stambolic V, Stiles B, Suzuki A, Tan SS, Tonks NK, Trotman LC, Wolff N, Woscholski R, Wu H, Leslie NR. (2014) A Uniform Nomenclature and Amino Acid Numbering for Human PTEN. Science Signal. 7: pe15PMCID:PMC4367864
14. Garcia, A.J., Ruscetti, M., Arenzana, T.L., Tran, L.M., Frias D.B., Sybert, E., Priceman, S.J., Wu, L., Nelson, P., Smale, S and Wu, H. (2014) Pten null prostate epithelium promotes localized MDSC expansion and immune suppression during tumor initiation and progression. Mol Cell Biol. 34:2017-2028. PMCID:PMC4019050
15. Mulholland, D., and Wu, H. (2013) A Book Chapter in “Stem Cells and Prostate Cancer”; Chapter 5 – Genetic and Signaling Pathway Regulations Springer Science-Business Media 77-89.
16. Smith, K.B., Tran, L.M., Tam, B.,Shurell, E.M., Li, Y., Braas, D., Tap, W.D., Christofk, H.R., Dry, S.M., Eiber, F.C., and Wu, H. (2013) Novel dedifferentiated liposarcoma xenograft models reveal PTEN down regulation as a malignant Signature and Response to PI3K Pathway Inhibition. American Journal of Pathology 182(4):1400-11. PMCID: PMC3620414.
17. Schlacher, K., Wu, H., and Jasin, M. (2012) A Distinct Replication Fork Protection Pathway Connects Fanconi Anemia Tumor Suppressors to RAD51-BRCA1/2. Cancer Cell 22(1):106-16. PMID: 22789542
2. 17. 14. Hubner, A., Mulholland, D., Standen, C., Karasarides, M., Cavanagh-Kyros, J., Barrett, T., Chi, H., Greiner, D., Tournier, C.,  Flavell, R., Sawyers, C., Wu H., and Davis, R. (2012) JNK and PTEN co-operatively control the development of invasive adenocarcinoma of the prostate. Proc. Natl. Acad. Sci. USA109(30):12046-51. PMCID: PMC3409732
3. 18. Mulholland, D., Kobayashi, N., Ruscetti, M., Zhi, A., Tran, L.M., Huang, J., Gleave, M and Wu, H (2012) Pten loss and RAS/MAPK activation coorperate to promote EMT and prostate cancer metastasis initiated from stem/progenitor cells. Cancer Res.72 (7):1878-89. PMCID: PMC3319847
4. 19. Tran, L.M., Chang, C., Plaisier, S., Dang, J., Mischel, P.S., Liao, J., Graeber, T.G. and Wu, H. (2012) Determining PTEN functional status by network component deducted transcription factor activities. PLoS One 7(2):e31053. PMCID: PMC 3275574
5. 20. Donahue, T.R., Tran, M.L., Hill, R., Li, Y, Kovochich, A., Calvopina, J., Patel, S.G., Farrell, J.J., Li, X., Dawson, D. and Wu, H. (2012) Integrative survival-based molecular profiling of Human Pancreatic Cancer. Clinic Cancer Res.18(5): 1352-63. PMID: 22261810
6. 21. Valamehr, B., Tsutsui, H., Ho, C.M., and Wu, H (2011) Developing defined culture system for human pluripotent stem cells. Regen. Med. 6:623-634. PMID: 21916597
7. 22. Mulholland, D., Tran, M.L., Cai, H., Morim, A., Wang, S., Plaisier, S., Huang, J., Garraway, I., Graeber, T. and Wu, H. (2011) Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 19, 792-804. PMCID:PMC3157296.
8. 23. Schlacher, K., Christ, N., Siaud, N., Egashira, A., Wu, H. and Jasin, M. (2011) Homologous recombination independent role for BRCA1 in blocking stalled replication folk degradation by MRE11. Cell145, 529-542. PMCID: PMC3261725
9. 24. Le Belle, J., Orozco, N.M., Paucar, A., Saxe, J., Mottahedeh, J., Pyle, A., Wu, H. and Kornblum, H. (2011) Proliferative neural stem cell maintain high endogenous levels of reactive oxygen species that regulate self-renewal and neurogenesis in a PI3K/AKT-dependent manner. Cell Stem Cell 8 (1): 59-71.PMCID: PMC3018289
10. 25. Guo, W., Schubbert, S., Chen, J-Y, Valamehr, V., Mosessian, S., Shi, H., Garcia, C., Theodoro, M.F., Varella-Garcia, M and Wu, H. (2011) Suppression of leukemia and leukemia stem cell transformation. Proc. Natl. Acad. Sci. USA 108, 1409-14.PMCID: PMC3029702
11. 26. Lukacs, R., Memarzadeh, S., Wu, H. and Witte, O (2010) Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation. Cell Stem Cell 7(6):682-93. PMCID: PMC3019762
12. 27. Tsutsui, H., Valamehr, B., Hindoyan, A., Qiao, R., Ding, X., Guo, S., Witte, O., Liu, X., Ho, C.M., and Wu, H. (2011) An optimized small molecule inhibitor cocktail supports long-term maintenance of human embryonic stem cells. Nature Communications 2:167. PMCID: PMC3161511
13. 28. Hill, R., Calvopina, J.H., Kim, C., Wang, Y., Dawson, D.W., Donahue, T.R., Dry, S., Wu, H. (2010) PTEN Loss Accelerates KrasG12D-Induced Pancreatic Cancer Development. Cancer Res 70 (18):7114-24.PMCID: PMC2940963
14. 29. Gregorian, G., Nakashima, J., Dry, S.M., Nghiemphu, P.L., Smith, K.B., Ao, Y., Dang, J., Lawson, G., Mellinghoff, I.K., Mischel, P.S., Phelps, M., Parada, L., Liu, X., Sofroniew, M.V., Eilber, F.C. and Wu, H. (2009) PTEN Dosage is Essential for Neurofibroma Development and Malignant Transformation.  Proc. Natl. Acad. Sci. USA 106: 19479-84. PMCID: PMC2765459
15. 30. Mosessian, S., Avliyakulov, N.K., Mulholland, D.J., Boontheung, P., Loo, J.A. and Wu, H. (2009) Analysis of PTEN Complex Assembly and Identification of Heterogeneous Nuclear Ribonucleoprotein C as a Component of the PTEN-associated Complex. J. Biol. Chem 284: 30159-66. PMCID: PMC2781571
16. 31. Mulholland, D.J., Xin, L., Morim, A., Lawson, D., Witte, O., and Wu, H (2009)Lin-Sca-1+CD49high stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res 69:8555-8562. PMCID: PMC2783355
17. 32. Guertin, D.A., Stevens, D.M., Saitoh, M., Crosby, K., Cormier, K.S., Mulholland, D.J., Magnuson, M.A., Wu, H., Sabatini, D.M. (2009) The mTOR complex 2 is required for the development of prostate cancer induced by PTEN loss in mice.  Cancer Cell 15:148-59. PMCID: PMC2701381
18. 33. Gregorian, C., Nakashima, J., Ohab, J., Kim, R., Liu, A., Groszer, M., Garcia, D., Sofroniew, M., Carmichael, T., Liu, X. and Wu, H. (2009) Pten Deletion in Adult Neural Stem/Progenitor Cells Enhances Constitutive Neurogenesis. J. Neuroscience 29: 1874-86. PMCID: PMC2754186
19. 34. Valamehr, B., Jonas, S., Polleux, J., Kam, K, Qiao, R., Stiles, B., Luo, T., Witte, O., Liu, X., Dunn, B. and Wu, H. (2008) Hydrophobic Surfaces for Enhanced Differentiation of Embryonic Stem Cells. Proc. Natl. Acad. Sci. USA 105:14459-64.PMCID: PMC2567159
20. 35. Burton JB, Johnson M, Sato M, Koh SB, Stout S, Mulholland D, Chatziioannou AF, Phelps M, Wu H. and Wu L. (2008) Adenovirus Mediated Gene Expression Imaging to Directly Detect Sentinel Lymph Node Metastasis of Prostate Cancer. Nature Med.14:882-9. PMCID: PMC2811163
21. 36. Kwon, C.H., Zhao, D., Chen, J., Alcantara, S., Li, Y., Burns, D., Mason, R.P., Lee, E.Y-H., Wu, H and Parada, L. (2008) Ptenhaploinsufficiency accelerates formation of high grade astrocytomas. Cancer Res. 68:3286-94. PMCID: PMC2760841
22. 37. Mulholland, D.J., Jiao, J. and Wu, H (2008) Hormone refractory prostate cancer: lesions leaned from the PTEN prostate cancer model. Adv Exp Med Biol 617:87-95. PMID:18497033
23. 38. Chang, C., Mulholland, D., Valamehr, B., Mosessian, S., Sellers, W. andWu, H. (2008) PTEN Nuclear Localization Is Regulated by Oxidative Stress and Responsible for p53-Dependent Tumor Suppression. Mol. Cell. Biol. 28:3281-9. PMCID: PMC2423144
24. 39. Guo, W., Lasky, J, Chang, C., Mosessian, S., Lewis, X., Xiao, Y., Yeh, J., Chen, J., Iruela-Arispe, L., Varella-Garcia, M. and Wu, H. (2008) Multi-genetic events collaboratively to Pten-null leukaemia stem-cell formation. Nature 453: 529-533.PMCID: PMC2840044
25. 40. Tahk S., Liu, B., Chenishof, V., Wong, K., Wu, H. and Shuai, K (2007) Control of specificity and magnitude of NF-kB and STAT1-mediated gene activation through PIASy and PIAS1 co-operation. Proc. Natl. Acad. Sci. USA 104: 11643-11648. PMCID: PMC1913887
26. 41. Jiao, J., Wang, S., Qiao, R., Vivanco, I., Watson, P., Sawyers, C. and Wu, H. (2007) Murine Cell Lines Derived from Pten Null Prostate Cancer Demonstrate the Critical Role of PTEN in Hormone Refractory Prostate Cancer Development. Cancer Res 67: 6083-91. PMID: 17616663
27. 42. Vivanco, I., Palaskas, N., Tran, C., Finn, S.P., Getz, G., Kennedy, N.G., Jiao, J., Rose, J., Xie, W., Loda, M., Golub, T., Mellinghoff, I., Davis, R., Wu, H. and Sawyers, C.L (2007) Identification of the JNK Signaling Pathway as a Functional Target of the Tumor Suppressor PTEN. Cancer Cell 11: 555-569. PMID:17560336
28. 43. He, X., Zhang, J., Grindley, J.C., Tian, Q., Sato, T., Tao, W.A., Dirisina, R., Porter-Westpfahl, K.S., Hembree, M., Johnson, T., Wiedemann, L., Barrett, T., Hood, L., Wu, H. and Li, L. (2007) Inactivation of PTEN leads to enhanced activation of intestinal stem cells and biasing on lineage fate determination. Nature Genetics 39: 189-98. PMID: 17237784
29. 44. Freeman, D., Lesche, R., Kertesz, N., Wang, S-Y., Li, G., Gao, J., Groszer, M., Martinez-Diaz, H., Rozengurt, N., Thomas, G., Liu, X., and Wu, H. (2006) Genetic Background Controls Tumor Development in Pten Deficient Mice. Cancer Res 66: 6492-6496. PMID:16818619
30. 45. Zhang, J., Grindley, J., Yin, T., Jayainghe, S., He, X., Ross, J., Haug, J., Rupp, D., Porter-Westpfahl, K., Wiedemann, L., Wu, H., and Li, L (2006) An essential role of PTEN in hematopoietic stem cell maintenance, lineage choice, and leukemia prevention. Nature 441: 518-522. PMID: 16633340
31. 46. Lei, Q., Jiao, J., Xin, L., Chang, C., Wang, S., Gao, J., Gleave, M.E., Witte, O., Liu, X. and Wu, H. (2006) NKX3.1 stabilizes p53, inhibits AKT activation and delays prostate cancer initiation caused by PTEN loss. Cancer Cell 9: 367-78. PMID:16697957
32. 47. Yilmaz, O.H., Valdez, R., Threisen, B.K., Guo, W., Ferguson, D.,O., Wu, H., Morrison, S.J. (2006) Pten dependence distinguishes hematopoietic stem cells from leukemia initiating cells. Nature 441: 475-482. PMID:16598206
33. 48. Li, G., Hu, Y., Liu, M., Huo, Y., Freeman, D., Gao, J., Liu, X., Wu, D-C., Wu, H. (2006) PTEN deletion leads to up-regulation of a secreted growth factor pleiotrophin. J. Biol. Chem. 281:10663-10668. PMID:16507572
34. 49. Stiles, B., Kurlawalla-Martinez, C., Guo, W., Gregorian, C., Wang, Y., Tian, J. Magnuson, M.A. and Wu, H. (2006) Selective deletion of Pten in pancreatic -cells leads to increased  cell mass and resistance to STZ-induced diabetes. Mol. Cell Biol. 26:2772-81. PMCID: PMC1430339
35. 50. Tsai, P., Ohab, J., Kertesz, N., Groszer, M., MatterC, Gao, J., Liu, X., Wu, H. and Carmichael, S.T. (2006) A Critical Role of Erythropoietin Receptor in Neurogenesis and post-stroke recovery. J. Neurosciences 26:126901274. PMID:16436614
36. 51. Wang, S., Garcia, A., Wu, M., Lawson, D., Witte, O. and Wu, H. (2006) Ptendeletion leads to the expansion of prostatic stem/progenitor cell subpopulation and tumor initiation. Proc. Natl. Acad. Sci. USA 103:1480-1485. PMCID: PMC1345717
37. 52. Groszer, M., Erickson, R., Scripture-Adams, D., Dougherty, J., LeBelle, J., Zack, J., Geschwind, D., Liu, X., Kornblum, H. and Wu, H. (2006) PTEN Negatively Regulates Neural Stem Cell Self-Renewal by Modulating G0-G1 Cell Cycle Entry. Proc. Natl. Acad. Sci. USA 103:111-116. PMCID: PMC1325011
38. 53. Stanger, B.Z., Stiles, B., Lauwers, G., Bardeesy, N., Mendoza, M., Wang, Y., Greenwood, A., Cheng, K., McLaughlin, P., Brown, D., DePinho, R., Wu, H., Melton D. and Dor Y. (2005) Supplemental data Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell 8:185-172. PMID:16169464
39. 54. Yue, Q., Groszer, M., Gil, J.S., Berk, A.J., Messing, A., Wu, H., Liu, X. (2005) PTEN deletion in Bergmann glia leads to premature differentiation and affects laminar organization. Development 132:3151-3326.PMID:15944184
40. 55. Sanchez, T., Thangada, S., Wu, M.T., Kontos, C., Wu, D., Wu, H. And Hla T. (2005) PTEN as an effector in the signaling of anti-migratory G protein-coupled receptor. Proc. Natl. Acad. Sci. USA 102:4312-7. PMCID: PMC555509
41. 56. Liu, B., Yang, R., Wong, K.A. Getman, C., Stein, N., Cheng, G., Wu, H., and Shuai K. (2005) Negative Regulation of NF-kB signaling by PIAS1. Mol. Cell Biol.25:1113-23. PMCID: PMCID: 544018
42. 57. Wu, H., Khodavirdi, A., and Roy-Burman, P (2005) Capturing Signal Anomalies of Human Prostate Cancer into Mouse Models. Chapter in “Prostate Cancer: Basic Mechanisms and Therapeutic Approaches” World Scientific Publishing Co. 393-421.
43. 58. Kurlawalla-Martinez, C., Stiles, B., Wang, Y., Devaskar, S., Kahn, B., and Wu, H. (2005) Insulin Hypersensitivity and Resistance to Streptozotocin Induced Diabetes in Mice Lacking PTEN in Adipose Tissue. Mol. Cell Biol. 25:2498-510. PMCID: PMC1061603
44. 59. Liu, B., Mink. S., Wong, K.A., Stein, N., Getman, C., Dempsey, P., Wu, H., Shuai, K. (2004) PIAS1 Selectively Inhibits a Subset of IFN-Inducible Genes and Is Important in Innate Immunity. Nature Immunology 5:891-898. PMID:15311277
45. 60. Kertesz, N., Wu, J., Chen, T., Sucov, H. and Wu,H. (2004) The role of erythropoietin in regulating angiogenesis. Devel. Biol. 276: 101-110. PMID:15531367
46. 61. Stiles, B., Groszer, M., Wang, S., Jiao, J. and Wu, H (2004) PTENless means more. Devel.  Biol. 273:175-184. PMID:15328005
47. 62. Chang, Chun-ju, Freeman, D. and Wu, H. (2004) PTEN regulates Mdm2 expression through the P1 promoter. J. Biol. Chem. 279:29841-29848. PMID:15090541
48. 63. Wong, K., Kim, R., Christofk, H., Gao, J. and Wu, H. (2004) Protein inhibitor of activated STAT Y (PIASy) enhances sumoylation but is not essential for embryogenesis and adult life. Mol. Cell Biol. 12:5577-5586. PMCID: PMC419860
49. 64. Stiles, B., Wang, Y., Stahl, A., Bassilian, S., Lee, W.P., Kim, Y-J., Sherwin R., Devaskar, S., Lesche, R., Magnuson, M., and Wu, H. (2004) Live-Specific Deletion of negative regulator Pten Results in Fatty Liver and Insulin Hypersensitivity. Proc. Natl. Acad. Sci. USA101: 2082-2087. PMCID: PMC357055
50. 65. Wang, S., Gao, J., Lei, Q-Y., Rozengurt, N., Pritchard, C., Jiao, J., Thomas, G., Li, G., Roy-Burman, P., Nelson, P., Liu, X., and Wu, H. (2003) Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4:209-221.PMID: 14522255
51. 66. Tsai, P., Lee, R.A., and Wu, H., (2003) BMP4 acts upstream of FGF in modulating thymic stroma and regulating thymopoiesis. Blood 102:3947-3953. PMID:12920023
52. 67. Wong, K., Tsai, P., Jegalian, A., Kertesz, N., Lee, R. and Wu, H. (2003) Erythropoietin, Biochemistry of. In Encyclopedia of Hormones Academic Press 561-569.
53. 68. Anzelon, A., Wu, H., and Rickert R. (2003) Pten Inactivation Alters Peripheral B Lymphocyte Fate and Reconstitutes CD19 Function. Nature Immunology 4:287-294. PMID:12563260
54. 69. Freeman, D., Wei, G., Li, H., Li, A., Lesche, R., Whale, A., Martinez-Diaz, H., Rozengurt, N., Liu, X. and Wu, H. (2003) PTEN Tumor Suppressor Gene Regulates p53 Through Both MDM2-Dependent and Independent Mechanisms. Cancer Cell 3:117-129.
55. 70. Li, G., Robinson, G.W., Lesche, R., Martinez-Diaz, H., Jiang, Z.R., Rozengurt, N., Wagner, K., Wu, D.C., Lane, T.F., Liu, X., Hennighausen, L., and Wu, H. (2002) Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development 129:4159-4170. PMID:12163417
56. 71. Stiles, B., Gilman, V., Khnzenzon, N., Lesche, R., Li, A., Qiao, R., Liu, X., and Wu, H. (2002) The Essential Role of AKT-1/PKB in PTEN Controlled Tumorigenesis. Mol. Cell. Biology 22: 3842-3851. PMCID: PMC133830
57. 72. Lesche, R., Groszer, M., Gao, J., Wang, Y., Messing, A., Liu, X., and Wu,H. (2002) Cre/loxp-Mediated Inactivation of The Murine Pten Tumor Suppressor Gene. Genesis32: 148-149. PMID: 11857804
58. 73. Jegalian, A., Acurio, A., Dranoff, G., Wu, H. (2002) Erythropoietin receptor haploinsufficiency and in vivo interplay with granulocyte-macrophage colony-stimulating factor and interleukine 3. Blood 99:2603-2605. PMID:11895800
59. 74. Jegalian, A. and Wu, H. (2002) Regulation of SOCS gene expression by the proto-oncogene Gfi-1B: Two Routes for STAT5-Target Gene Induction by Erythropoietin. J. Biol. Chem. 277: 2345-2352. PMID:11696536
60. 75. Groszer, M., Erickson, R., Scripture-Adams, D., Lesche, R., Trumpp, A., Zack, J., Kornblum, H., Liu, X., and Wu, H. (2001) Negative Regulation of Neural Stem/Progenitor Cell Proliferation by the Pten Tumor Suppressor Gene In Vivo. Science 294: 2186-2189. PMID:11691952
61. 76. Neshat, M., Mellinghoff, I., Tran, C., Stiles, B., Thomas, G., Wu, H., and Sawyers, C. (2001) Enhanced sensitively of PTEN-Deficient Tumors to Inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA 98: 10314-10319. PMCID: PMC56958
62. 77. Lee, R., Kertesz, N., Joseph, S., Jegalian, A. and Wu, H. (2001) Erythropoietin (Epo) and EpoR Expression and Two Waves of Erythropoiesis. Blood 98: 1408-1415.
63. 78. Liliental,J., Lesche, R., Moon, S-Y., Mamillapalli, R., Gavrilova, N., Sun, H., Zheng, Y., and Wu, H. (2000) Genetic Deletion of the Pten Tumor Suppressor Gene Promotes Cell Motility by Activation of Rac1 and Cdc42 GTPases. Current Biology10,401-404. PMID:10753747
64. 79. Wu, H., Lee, S-H, Gao, J., Liu, X. and Iruela-Arispe, L. (1999) Inactivation of Erythropoietin Leads to Defects in Cardiac Morphogenesis. Development 126:3597-3605. PMID:10409505
65. 80. Sun, H., Lesche, R., Li, DM., Liliental, J., Zhang, H., Gao, J., Garvarina, N., Mueller, B., Liu, X. and Wu, H. (1999) PTEN Modulates Cell Cycle Prograssion and Cell Survival by Regulating PIP3 and AKT/PKB Signaling Pathway. Proc. Natl. Acad. Sci. USA 96: 6199-6204. PMCID: PMC26859
66. 81. Klingmuller, K., Wu, H., Hsiao, J., Duckworth, B., Toker, A., Cantley, L.C. and Lodish, H.F. (1997) Identification of a novel pathway important for proliferation and differentiation of primary erythroid progenitors. Proc. Natl. Acad. Sci. USA 94, 3016-3021. PMCID: PMC20314
67. 82. Liu, X., Wu, H., Loring, J., Hormuzdi, S., Disteche, C. M., Bornstein, P. and Jaenisch, R. (1997) Trisomy eight in ES cells is a common potential problem in gene targeting and interferes with germ line transmission. Developmental Dynamics 209, 85-91. PMID:9142498
68. 83. Wu, H., Klingmüller, U., Acurio, A., Hsiao, J. G. and Lodish, H. F. (1997) Functional Interaction of Erythropoietin and Stem Cell Factor Receptors is Essential for Erythroid Colony Formation. Proc. Natl. Acad. Sci. USA. 94, 1806-1810. PMCID: PMC19998
69. 84. Liu, X., Wu, H. and Jaenisch, R. (1997). Type III collagen is crucial for collagen I fibrillogenesis and for normal cardiovascular development. Proc. Natl. Acad. Sci. USA 94, 1852-1856.PMCID: PMC 20006
70. 85. Wu, H. and Lodish, H.F. (1996) The erythropoietin receptor: dimerization and intracellular signal transduction. Journal of Experimental Hematology. 4, 229-235.
71. 86. 83. Watowich, S.S., Wu, H., Socolovsky, M., Klingmuller, U., Constantinescu, S.N. and Lodish, H.F. (1996). Cytokine receptor signal transduction and the control of hematopoietic cell development.  Ann. Rev. Cell. Devel.12, 91-128. PMID:8970723
72. 87. Byrne, M., Eeckhout, Y., Henriet, P., Lemaǐtre, V., Jeffrey, J.J., Witter, J., Liu, X., Wu, H., Jaenisch, R. and Krane, S.M. (1996). Different collagenase gene products have different roles in remodeling of type I collagen-containing extracellular matrices. J. Biol. Chem. 271, 28509-28515. PMID:8910479
73. 88. Lodish, H., Hilton, D., Klingmuller, U., Watowich, S. and Wu, H. (1995). The erythropoietin receptor: biogenesis, dimerization, and intracellular signal transduction. Cold Spring Harbor Symp, LX, 93-104. PMID:8824381
74. 89. Wu, H., Liu, X., Jaenisch, R. and Lodish, H. (1995). Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 83, 59-67. PMID:7553874
75. 90. Wu, H., Klingmüller, U., Besmer, P. and Lodish, H. (1995). Interaction of the erythropoietin and stem cell factor receptors. Nature 377, 242-246. PMID:7545788
76. 91. Liu, X., Enfors, P., Wu, H. and Jaenisch, R. (1995). Mice lacking NT-4 or both NT-4 and BDNF develop with sensory neuron deficit, but show no motor neuron loss. Nature 375, 238-241.
77. 92. Liu, X., Wu, H., Byrne, M., Jeffrey, J., Krane, S. and Jaenisch, R. (1995)A targeted mutation at the known collagenase cleavage site in mouse type I collagen impairs tissue remodeling. J. Cell. Biol. 130, 227-237. PMCID: PMC2120510
78. 93. 90. Wu, H., Liu, X. and Jaenisch, R. (1994) Double replacement: strategy for efficient introduction of subtle mutations into the murine Col1a-1 gene by homologous recombination in embryonic stem cells.  Proc. Natl. Acad. Sci. USA91, 2819-2823. PMCID:PMC43462
79. 94. Wu, H., Faessler, R., Schnieke, A., Barker, D., Chapman, V., Francke, U. and Jaenisch, R. (1992). A X-linked human collagen transgene escapes X inactivation in a subset of cells. Development 116: 687. PMID:1289060
80. 95. Wu, H., Byrne, M.H., Stacey, A., Goldring, M.B., Birkhead, J.R., Jaenisch, R. and Krane, S.M. (1990). Generation of collagenase resistant collagen by site-directed mutagenesis of murine pro1 (l) collagen gene. Proc. Natl. Acad. Sci. U.S.A87, 5888-5892. PMCID:PMC54434
81. 96. Wu, H., Bateman, J.F., Schnieke, A., Sharpe, A., Barker, D., Mascara, T., Eyre, D., Bruns, R., Krimpenfort, P., Berns, A. and Jaenisch, R (1990). Human-mouse interspecies collagen I heterotrimer is functional during embryonic development of Mov13 mutant mouse embryos.  Mol. Cell. Biology10: 1452-1460. PMCID:PMC362247
Laboratory Introduction